Pharma Focus Asia

Scorpion Therapeutics Announces Collaboration and Licence Agreement with Pierre Fabre

Wednesday, April 05, 2023

Scorpion Therapeutics and Pierre Fabre announced an exclusive collaboration and licence agreement for the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor (“EGFR”) inhibitors.

Under the agreement, Scorpion will lead clinical development of STX-721 and Pierre Fabre will lead clinical development of STX-241. Scorpion will retain commercialisation rights to STX-721 and STX-241 in the United States, Canada and Japan, and Pierre Fabre will be responsible for commercialisation activities in all other territories, with a focus on Europe and China.

Based on the preclinical data, that STX-721 and STX-241 will present best-in-class product profiles. Further, this partnership will significantly expand efforts in precision oncology, to better support the care and treatment of thousands of people globally.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Asia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024
Charles river - Endosafe Trillium